By América Torres
In the fascinating world of cardiology, continuous research drives significant advancements that shape the future of cardiovascular healthcare. The year 2023 has witnessed notable clinical trials that promise to transform the prevention, diagnosis, and treatment of heart diseases. From innovative therapies to pioneering management strategies, this selection highlights the most intriguing studies that have captured the medical community's attention, providing a revealing glimpse into what lies ahead. Click on the name of the clinical trial that interests you to view the original document.
Sphericity Predicts Cardiomyopathy
Clinical trial:Deep learning-enabled analysis of medical images identifies cardiac sphericity as an early marker of cardiomyopathy and related outcomes. Milos Vukadinovic et al.
Highlights: Measurement of left ventricular sphericity can be automated using deep learning. Sphericity predicts incident cardiomyopathy independent of traditional factors. Genome-wide association study of sphericity identifies loci relevant to cardiomyopathy.
Reconsidering Return-to Play for Elite Athletes With Heart Disease
Reconsidering Return-to Play for Elite Athletes With Heart Disease
Clinical trial:Return-to-Play for Elite Athletes With Genetic Heart Diseases Predisposing to Sudden Cardiac Death.
Highlights: People diagnosed with genetic heart diseases associated with sudden cardiac death have historically been restricted from participating in competitive sports. Recent data documenting experiences of return to sports activity after shared decision making suggest that cardiac event rates for this type of athletes are lower than previously described. This study suggests reconsidering the paradigm.
Healthcare Professionals Are Not Prescribing LLT as Guidelines Indicate
Healthcare Professionals Are Not Prescribing LLT as Guidelines Indicate
Clinical trial:2% of High-Risk Hypercholesterolemia Patients Never Reach Below ACC/AHA Guideline LDL-C Thresholds. Katherine A. Wilemon et al.
Highlights: This study revealed insightful figures regarding the need to place greater emphasis on treatment to reduce LDL cholesterol. Among other interesting statistics, the document reported that 79.5% of healthcare professionals never prescribed combination lipid-lowering therapies (LLT) despite guidelines providing direction and rationale for doing so. Additionally, only 2.2% of high-risk patients received combination LLT.Keto Diet Can Increase The Risk of Heart Disease
Keto Diet Can Increase The Risk of Heart Disease
Clinical trial:‘Keto-Like’ Diet May Be Linked to Higher Risk of Heart Disease, Cardiac Events. Iulia Iatan et al.
Highlights: This research demonstrated that a low-carbohydrate, high-fat diet was associated with elevated levels of LDL cholesterol and an increased risk of heart disease.
Semaglutide Can Help Obese Patients with STEP-HFpEF
Semaglutide Can Help Obese Patients with STEP-HFpEF
Clinical trial:STEP-HFpEF: Semaglutide Improves Symptoms, Physical Limitations, Weight Loss in Patients With HFpEF and Obesity. Dharam J. Kumbhani.
Highlights: This clinical trial showed that a weekly subcutaneous injection of semaglutide was superior to placebo in helping obese patients with heart failure with preserved ejection fraction to reduce their body weight and improve their quality of life at 52 weeks.
These studies, reflecting the scientific community's unwavering commitment to excellence, inspire us. The perseverance of researchers compels us to remain dedicated to developing medical devices that assist them in their challenging work to achieve a future free from heart diseases.
